WeightWatchers will begin selling compounded alternatives to certain weight-loss drugs that are experiencing shortages. Why it matters: Federal law allows companies to sell compounded versions of drugs that are on the FDA's shortages list — which has led to a surge of copycats to the newly popular class of GLP-1 injections.

Lots of people want to lose weight but they don't necessarily want to take regular injections to do it. That's the finding of a new national survey. It fou

Weight-loss jabs will be rolled out across the NHS for the first time in an effort to tackle obesity. Health officials have announced plans to offer injections of Mounjaro - the most effective on the market - to 1.6 million people. NHS England proposed that the jabs should first go to those likely to achieve the greatest clinical benefit.

The ecosystem of companies competing to develop therapies for weight loss is growing every day, and there's more than one competitor that's investment-ready. While many investors look to small and risky biotechs to get exposure, there are larger and safer options, too.

Key Takeaways Shares of WW International, better known as WeightWatchers, soared Tuesday after it said it is offering copycat weight-loss drugs to its members.The compounded treatments will contain the same active ingredient as Novo Nordisk's weight-loss medicines.